<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03051685</url>
  </required_header>
  <id_info>
    <org_study_id>DFN-15-CD-003</org_study_id>
    <nct_id>NCT03051685</nct_id>
  </id_info>
  <brief_title>Bioavailability of DFN-15 at 3 Different Doses vs. Comparator and to Determine Dose-proportionality of DFN-15 in Fasting Healthy Adults</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Crossover study to compare the BA of DFN-15 at 3 different doses versus the comparator to&#xD;
      determine dose-proportionality of DFN-15 in healthy volunteers under fasting conditions&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 20, 2015</start_date>
  <completion_date type="Actual">November 10, 2015</completion_date>
  <primary_completion_date type="Actual">August 14, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters of DFN-15</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>DFN-15 maximum Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters of DFN-15</measure>
    <time_frame>15 minutes</time_frame>
    <description>Area under the curve (AUC) 0-15 min</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters of DFN-15</measure>
    <time_frame>30 minutes</time_frame>
    <description>Area under the curve (AUC) 0-30</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters of DFN-15</measure>
    <time_frame>1 hour</time_frame>
    <description>Area under the curve (AUC) 0-1 hour</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters of DFN-15</measure>
    <time_frame>2 hours</time_frame>
    <description>Area under the curve (AUC) 0-2 hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters of DFN-15</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>Area under the curve (AUC) 0-T</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters of DFN-15</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>Area under the curve (AUC) 0-RefTmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters of DFN-15</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>Area under the curve (AUC) 0-∞</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>DFN-15 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DFN-15 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DFN-15 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFN-15 Dose 1</intervention_name>
    <arm_group_label>DFN-15 Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFN-15 Dose 2</intervention_name>
    <arm_group_label>DFN-15 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFN-15 Dose 3</intervention_name>
    <arm_group_label>DFN-15 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Comparator</intervention_name>
    <arm_group_label>Active Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects were male or female, at least 18 years of age but not older than 45 years of age.&#xD;
        The main inclusion criteria were:&#xD;
&#xD;
          1. non- or ex-smokers&#xD;
&#xD;
          2. body mass index (BMI) ≥18.50 kg/m2 and &lt;30.00 kg/m2&#xD;
&#xD;
          3. no clinically significant abnormality found in the 12-lead ECG performed at study&#xD;
             entry&#xD;
&#xD;
          4. negative pregnancy test for female subjects&#xD;
&#xD;
          5. healthy according to medical history, complete physical examination (including vital&#xD;
             signs) and laboratory tests (general biochemistry, hematology, urinalysis, and&#xD;
             coagulation)&#xD;
&#xD;
          6. Fecal occult blood determination negative at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who were pregnant or were lactating&#xD;
&#xD;
          2. Patients who had a history of allergic reactions to non-steroidal anti-inflammatory&#xD;
             drugs (NSAIDs), including patients in whom aspirin or other NSAIDs induce the syndrome&#xD;
             of asthma, rhinitis, nasal polyps or Samter's triad&#xD;
&#xD;
          3. Presence of significant gastrointestinal, liver or kidney disease, or any other&#xD;
             conditions known to interfere with the absorption, distribution, metabolism or&#xD;
             excretion of drugs or known to potentiate or predispose to undesired effects&#xD;
&#xD;
          4. History of significant gastrointestinal, liver or kidney disease that may affect drug&#xD;
             bioavailability&#xD;
&#xD;
          5. Presence of significant cardiovascular, pulmonary, hematologic, neurological,&#xD;
             psychiatric, endocrine, immunologic or dermatologic disease&#xD;
&#xD;
          6. Suicidal tendency, history of or disposition to seizures, state of confusion,&#xD;
             clinically relevant psychiatric diseases, neurological impairment or cognitive&#xD;
             dysfunction that, in the opinion of the investigator, would compromise validity of&#xD;
             informed consent, study participation and compliance or data collection&#xD;
&#xD;
          7. Presence of out-of-range cardiac intervals and/ or morphological changes suggestive of&#xD;
             arrhythmias or ischaemic heart disease on the screening electrocardiogram (ECG) or&#xD;
             other clinically significant ECG abnormalities&#xD;
&#xD;
          8. History or current hypertension, bleeding disorders, ischaemic heart disease, stroke&#xD;
             and/or cerebrovascular disease or renal disease&#xD;
&#xD;
          9. History of asthma, urticaria, or allergic-type reactions after taking acetylsalicylic&#xD;
             acid (ASA) or other NSAIDs&#xD;
&#xD;
         10. Presence or history of gastric, duodenal or peptic ulcer or gastrointestinal bleeding&#xD;
&#xD;
         11. Use of ASA or NSAIDs, or any product containing ASA or NSAIDs, in the previous 7 days&#xD;
             before day 1 of this study&#xD;
&#xD;
         12. Known presence of rare hereditary problems of galactose and /or lactose intolerance,&#xD;
             Lapp lactase deficiency or glucose-galactose malabsorption&#xD;
&#xD;
         13. Maintenance therapy with any drug or significant history of drug dependency (including&#xD;
             marijuana and medical marijuana) or alcohol abuse (&gt; 3 units of alcohol per day,&#xD;
             intake of excessive alcohol, acute or chronic) within 1 year&#xD;
&#xD;
         14. Any clinically significant illness in the previous 28 days before day 1 of this study&#xD;
&#xD;
         15. Any history of tuberculosis and/or prophylaxis for tuberculosis&#xD;
&#xD;
         16. Positive urine screening of alcohol and/or drugs of abuse&#xD;
&#xD;
         17. Positive results to HIV Ag/Ab Combo, Hepatitis B surface Antigen (HBsAG (B)) or anti&#xD;
             Hepatitis C Virus (HCV (C)) tests&#xD;
&#xD;
         18. Females who were pregnant according to a positive pregnancy test&#xD;
&#xD;
         19. Volunteers who took an investigational product (in another clinical trial) in the&#xD;
             previous 28 days before day 1 of this study or who had already participated in this&#xD;
             clinical study&#xD;
&#xD;
         20. Volunteers who donated plasma in the previous 14 days before day 1 of this study&#xD;
&#xD;
         21. Donation of 500 mL or more of blood (American Red Cross, clinical studies, etc.) in&#xD;
             the previous 56 days before day 1 of this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site 1</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Pal A, Shenoy S, Gautam A, Munjal S, Niu J, Gopalakrishnan M, Gobburru J. Pharmacokinetics of DFN-15, a Novel Oral Solution of Celecoxib, Versus Celecoxib 400-mg Capsules: A Randomized Crossover Study in Fasting Healthy Volunteers. Clin Drug Investig. 2017 Oct;37(10):937-946. doi: 10.1007/s40261-017-0548-6.</citation>
    <PMID>28748412</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>February 7, 2017</study_first_submitted>
  <study_first_submitted_qc>February 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2017</study_first_posted>
  <last_update_submitted>February 10, 2018</last_update_submitted>
  <last_update_submitted_qc>February 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

